Coronavirus Medicine
(Source News Straits Times)
One in three South Korean Covid-19 patients
improve with remdesivir drug.
One
in three South Korean patients seriously ill with Covid-19 showed improvement
after being given Gilead Sciences antiviral medication, health authorities
said.
More
research is needed to determine if the increase is due to medications or other
factors such as patient immunity and other therapies, they said. Remdesivir has
been at the forefront of the global battle against Covid-19 after intravenously the administered medication helped shorten hospital recovery time in U.S. clinical
trials.
Several
countries including South Korea have added the drug to the list of treatments
for diseases caused by the novel coronavirus. No vaccine has been approved for
him. In a recent update on the drug, Gilead said last Friday (July 10) that
analysis showed remdesivir helped reduce the risk of death in critically ill
Covid-19 patients, but reminded that rigorous clinical trials are needed to
confirm its benefits.
The
Korean Centers for Disease Control and Prevention reported last Saturday the
results of the first batch of 27 patients given remdesivir at different
hospitals. Nine patients showed improvement in their condition, 15 showed no
change, and three worsened, KCDC Deputy Director Kwon Jun-Wook said at the
briefing. The results have yet to be compared with the control group and more
analysis is needed to conclude the benefits of remdesivir, said Mr. Kwon.
In
June, South Korea asked Gilead to supply enough of its medicine to treat more
than 5,000 Covid-19 patients in preparation for a possible secondary infection.
South
Korea has fought a small but ongoing outbreak of the new coronavirus, with 62
new cases reported on Sunday, bringing the country’s total to 13,479 cases with
289 deaths.
Comments
Post a Comment